In a letter published in HemaSphere, Claudia Bellofiore, MD, of the University of Pavia in Italy, and colleagues highlighted the need to expand clinical trial eligibility criteria for patients with immunoglobulin light chain (AL) amyloidosis due to the “critical impact” it has on treatment and survival.
AL amyloidosis research and treatment has been limited, with few clinical trials assessing upfront anti-plasma cell therapies. Recent phase 3 trials, however, have resulted in the approval of the current standard of care, though clinical evidence for the treatment of AL amyloidosis is primarily based on retrospective studies.